info@cymabay.com
(510) 293-8800
Home
About
Overview
Management Team
Board of Directors
Careers
Clinical Trials
Pipeline
Overview
Seladelpar
Additional Programs
Expanded Access
Clinical Trials
Collaborations
News
Press Releases
Upcoming Events
Investors
Contact
Investors
Home
/
Investors
/
Press Releases
Press Releases
Overview
News / Events
Press Releases
Events
Presentations
Publications
Email Alerts
Company Information
Profile
Management Team
IR Contacts
FAQ
Financial Information
Financials
Quarterly Results
Stock Data
Quote
Charts
Historical Data
Analyst Coverage
SEC Filings
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
Corporate Governance
Board of Directors
Board Committees
Governance Docs
Email Alerts
IR Contacts
RSS News Feed
All News
By Year:
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
20
Nov
CymaBay Therapeutics to Participate in Upcoming Investor Conferences
13
Nov
CymaBay Therapeutics Presents Positive Results from its Ongoing Phase 2 Study of Seladelpar in Patients with PBC at The Liver Meeting® 2018
6
Nov
CymaBay Reports Third Quarter 2018 Financial Results and Provides Corporate Update
30
Oct
CymaBay to Report Third Quarter 2018 Financial Results on Tuesday, November 6
30
Oct
CymaBay Announces the Initiation of the Seladelpar Global Phase 3 Registration Study (ENHANCE) for the Treatment of Primary Biliary Cholangitis and Additional Corporate Updates
3
Oct
CymaBay Therapeutics Announces Additional Positive Results from its Ongoing Phase 2 Study of Seladelpar in Patients with PBC will be Presented During the Late-Breaking Session at The Liver Meeting®
24
Sep
CymaBay Therapeutics to Participate in Upcoming Investor Conferences in October
14
Aug
CymaBay Therapeutics to Participate in Upcoming Investor Conferences in August and September
9
Aug
CymaBay Reports Second Quarter 2018 Financial Results and Provides Corporate Update
2
Aug
CymaBay to Report Second Quarter 2018 Financial Results on Thursday, August 9
1
2
3
Next >>
Show All
Scroll
